Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.050.166 |
Chemical and physical data | |
Formula | C8H10N4O2 |
Molar mass | 194.194 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Enprofylline (3-propylxanthine) is a xanthine derivative used in the treatment of asthma, which acts as a bronchodilator. It acts primarily as a competitive nonselective phosphodiesterase inhibitor with relatively little activity as a nonselective adenosine receptor antagonist.
References
- Lunell E, Svedmyr N, Andersson KE, Persson CG (1982). "Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease". European Journal of Clinical Pharmacology. 22 (5): 395–402. doi:10.1007/bf00542541. PMID 6288396. S2CID 3240010.
- Laursen LC (December 1987). "Anti asthmatic effects and pharmacokinetics of enprofylline--a new xanthine derivate". Danish Medical Bulletin. 34 (6): 289–97. PMID 3325233.
Phosphodiesterase inhibitors | |
---|---|
PDE1 | |
PDE2 | |
PDE3 | |
PDE4 |
|
PDE5 | |
PDE7 | |
PDE9 | |
PDE10 | |
PDE11 | BC11-38 |
Non-selective | |
Unsorted | |
See also: Receptor/signaling modulators |
Purine receptor modulators | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Receptor (ligands) |
| ||||||||||
Transporter (blockers) |
| ||||||||||
Enzyme (inhibitors) |
| ||||||||||
Others |
| ||||||||||
See also: Receptor/signaling modulators |